Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Parabilis Medicines, Inc.PBLS · Entity 3933 | See Remarks | June 09, 2026 | June 10, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Parabilis Medicines, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2034-03-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2034-03-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of the shares subject to this option vested and became exercisable on October 23, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2036-02-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-06-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F2: 25% of the shares subject to this option vested and became exercisable on October 23, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F3: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,014 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 5,014 F1: Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228888 · ownership.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228888 · ownership.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,014 F1 · shares: Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:38 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $123.26 | $0.00 |
DisclosureSEC source: 0000950170-25-074196 · ownership.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 15, 2025 Filed May 19, 2025 18:38 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 973 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074196 · ownership.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,019 F1 · shares: Mr. Mhatre was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:32 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,376 | $0.00 Strike: $171.03 | $0.00 |
DisclosureSEC source: 0000950170-24-062619 · ownership.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,376 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:32 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062619 · ownership.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,046 F1 · shares: Mr. Mhatre was awarded 701 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:36 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,487 | $0.00 Strike: $156.63 | $0.00 |
DisclosureSEC source: 0000899243-23-013692 · doc4.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487 Underlying: Common Stock · 1,487 shares Expires 2033-05-18 F2 · derivative.exercise_date: Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:36 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 686 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013692 · doc4.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,345 F1 · shares: Mr. Mhatre was awarded 686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:25 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,920 | $0.00 Strike: $159.17 | $0.00 |
DisclosureSEC source: 0000899243-22-020284 · doc4.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,920 Underlying: Common Stock · 2,920 shares Expires 2032-05-26 F2 · derivative.exercise_date: Award vests in full on the earlier of May 26, 2023, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:25 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,202 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020284 · doc4.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,659 F1 · shares: Mr. Mhatre was awarded 1,202 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 26, 2023, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:50 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $169.65 | $0.00 |
DisclosureSEC source: 0000899243-21-019706 · doc4.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-13 F2 · derivative.exercise_date: Award vests in full on the earlier of May 13, 2022, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:50 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019706 · doc4.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457 F1 · shares: Mr. Mhatre was awarded 457 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 13, 2022, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:59 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 3,452 | $0.00 Strike: $85.60 | $0.00 |
DisclosureSEC source: 0000899243-20-006771 · doc4.xml · derivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,452 Underlying: Common Stock · 3,452 shares Expires 2030-03-01 F1 · derivative.exercise_date: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.